<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1167</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2006-2-3-37-39</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железы</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Integral estimate of the parameters of transrectal multifocal rebiopsy in the diagnosis of prostate cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Интегральная оценка параметров повторной трансректальной мультифокальной биопсии в диагностике рака предстательной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Petrov</surname><given-names>S. B.</given-names></name><name xml:lang="ru"><surname>Петров</surname><given-names>С. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Clinic of Urology</p></bio><bio xml:lang="ru"><p>Клиника урологии</p><p>Санкт-Петербург</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Veliyev</surname><given-names>Ye. I.</given-names></name><name xml:lang="ru"><surname>Велиев</surname><given-names>Е. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yeloyev</surname><given-names>R. A.</given-names></name><name xml:lang="ru"><surname>Елоев</surname><given-names>Р. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Clinic of Urology</p></bio><bio xml:lang="ru"><p>Клиника урологии</p><p>Санкт-Петербург</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lysenko</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Лысенко</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Clinic of Urology</p></bio><bio xml:lang="ru"><p>Клиника урологии</p><p>Санкт-Петербург</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Military Medical Academy, Saint Petersburg</institution></aff><aff><institution xml:lang="ru">Военно-медицинская академия им. С.М. Кирова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Postgraduate Education</institution></aff><aff><institution xml:lang="ru">РМАПО</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2006-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2006</year></pub-date><volume>2</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>37</fpage><lpage>39</lpage><history><date date-type="received" iso-8601-date="2020-02-18"><day>18</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-02-18"><day>18</day><month>02</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1167">https://oncourology.abvpress.ru/oncur/article/view/1167</self-uri><abstract xml:lang="en"><p><bold>Materials and Methods.</bold> The results of transrectal multifocal prostatic rebiopsy made under ultrasound guidance at the Clinic of Urology, Military Medical Academy, in 1998 to 2004 were studied.</p><p>A total of 2352 males were examined; of them, 125 patients underwent rebiopsy. The patients’ age was 54 to 87 years (mean age 60.3 years). The patients were divided into 4 age groups: 1) 51-60 years [11% (14/125)]; 2) 61-70 years [47% (59/125)]; 3) 71-80 years [35% (44/125)]; 4) &gt; 81 years [0.3% (4/125)]. There were 6 to 14 biopsy probes.</p><p><bold>Results.</bold> The study showed that rebiopsy of the prostate identified its cancer in 23% of the patients having a negative primary histological result. It was also established that the patients in whom primary biopsy revealed prostatic intraepithelial neoplasia (PIN) and/or an increase in PSA of &gt; 0.75 ng/ml per year and its density &gt; 0.15 ng/ml/cm3 should be referred to a repeated histological study within 6 to 12 months. When these rules were observed, there were the most favorable prognostic signs: no capsular invasion, lower Glisson scores, and none metastasis.</p><p><bold>Conclusion.</bold> The study has provided the following indications for rebiopsy:</p><p>— a continually elevating PSA level or its preservation after primary negative biopsy;</p><p>— abnormal findings on rectal examination and transrectal ultrasound study;</p><p>— high-grade PIN in the prior biopsy specimen.</p></abstract><trans-abstract xml:lang="ru"><p>.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 31: 8–31.</mixed-citation><mixed-citation xml:lang="ru">Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 31: 8–31.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М.; 1999. с. 5.</mixed-citation><mixed-citation xml:lang="ru">Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М.; 1999. с. 5.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Djavan B., Zlotta A.R., Remzi M. et al. Optimal predictors of prostate cancer in repeat prostate biopsy: a prospective study in 1051 men. J Urol 2000; 163(4): 1144–8.</mixed-citation><mixed-citation xml:lang="ru">Djavan B., Zlotta A.R., Remzi M. et al. Optimal predictors of prostate cancer in repeat prostate biopsy: a prospective study in 1051 men. J Urol 2000; 163(4): 1144–8.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Seidman H., Mushinski M.H., Gelb S.K., Silverberg E. Probabilities of eventually developing or dying of cancer in United States 1985. CA Cancer J Clin 1985; 35: 36–56.</mixed-citation><mixed-citation xml:lang="ru">Seidman H., Mushinski M.H., Gelb S.K., Silverberg E. Probabilities of eventually developing or dying of cancer in United States 1985. CA Cancer J Clin 1985; 35: 36–56.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Morgan T.O., McLeod D.G., Leifer E.S. et al. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48: 76–80.</mixed-citation><mixed-citation xml:lang="ru">Morgan T.O., McLeod D.G., Leifer E.S. et al. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48: 76–80.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Djavan B., Remzi M., Marberger M. When and how a prostatic rebiopsy should be performed? Eur Urol Suppl 2002;1 (6): 52–9.</mixed-citation><mixed-citation xml:lang="ru">Djavan B., Remzi M., Marberger M. When and how a prostatic rebiopsy should be performed? Eur Urol Suppl 2002;1 (6): 52–9.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Hendrikx A., Safarik L., Hammerer P. TRUS and biopsy: practical aspects. Eur Urol 2002; 41(6): 1–10.</mixed-citation><mixed-citation xml:lang="ru">Hendrikx A., Safarik L., Hammerer P. TRUS and biopsy: practical aspects. Eur Urol 2002; 41(6): 1–10.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Gretzer M.B., Partin A.W. PSA levels and the probability of prostate cancer on biopsy. Eur Urol Suppl 2002; 1 (6): 21–7.</mixed-citation><mixed-citation xml:lang="ru">Gretzer M.B., Partin A.W. PSA levels and the probability of prostate cancer on biopsy. Eur Urol Suppl 2002; 1 (6): 21–7.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
